Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2014; 139(12): 608
DOI: 10.1055/s-0033-1360078
DOI: 10.1055/s-0033-1360078
Korrespondenz | Correspondence
Frage aus der Praxis
Alte Wirkstoffe in neuem Gewand – Losartan und Fenofibrat als potenzielle Gicht-Therapeutika?
A new application for well-known pharmaceutics – Losartan and Fenofibrate as potential remedies against gout?Further Information
Publication History
Publication Date:
11 March 2014 (online)
Frage: Ein Patient berichtet davon, dass sich seine Gichtsymptomatik verbessert hat, seitdem er zur Blutdrucksenkung regelmäßig Losartan einnimmt. Für ihn und seinen behandelnden Arzt stellt sich daraufhin die Frage, ob dies eine mögliche Begleitwirkung des AT1-Rezeptor-Antagonisten sein könne.
-
Literatur
- 1 Alderman M. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002; 2: 126-130
- 2 American College of Rheumatology. Guidelines for Management of Gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012; 64: 1431-1446
- 3 Elisaf M. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol 1999; 34: 60-63
- 4 Fachinformation Zyloric®. 2008
- 5 Ito S et al. Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan. Hypertension Reasearch 2012; 35: 867-873
- 6 Wall GC, Cooper SA. Gout and hyperuricemia: new guidelines and treatments. J Pharmacy Pract 2008;
- 7 Zhang W et al. EULAR Evidence Based Recommendations For Gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-1324